bioRxiv Science⌕ Search

bioRxiv · 10.1101/2023.05.03.539189

A multi-network approach to Alzheimers Disease gene prioritization complements cis-regulatory prioritization with molecular quantitative trait loci

Abstract

Gene prioritization within mapped disease-risk loci from genome-wide association studies (GWAS) remains one of the central bioinformatic challenges of human genetics. This problem is abundantly clear in Alzheimers Disease (AD) which has several dozen risk loci, but no therapeutically effective drug target. Dominant strategies emphasize alignment between molecular quantitative trait loci (mQTLs) and disease risk loci, under the assumption that cis-regulatory drivers of gene expression or protein abundance mediate disease risk. However, mQTL data do not capture clinically relevant time points or they derive from bulk tissue. These limitations are particularly significant in complex diseases like AD where access to diseased tissue occurs only in end-stage disease, while genetically encoded risk events accumulate over a lifetime. Network-based functional predictions, where bioinformatic databases of gene interaction networks are used to learn disease-associated gene networks to prioritize genes, complement mQTL-based prioritization. The choice of input network, however, can have a profound impact on the output gene rankings, and the optimal tissue network may not be known a priori. Here, we develop a natural extension of the popular NetWAS approach to gene prioritization that allows us to combine information from multiple networks at once. We applied our multi-network (MNFP) approach to AD GWAS data to prioritize candidate genes and compared the results to baseline, single-network models. Finally, we applied the models to prioritize genes in recently mapped AD risk loci and compared our prioritizations to the state-of-the-art mQTL approach used to functionally prioritize genes within those loci. We observed a significant concordance between the top candidates prioritized by our MNFP method and those prioritized by the mQTL approach. Our results show that network-based functional predictions are a strong complement to mQTL-based approaches and are significant to the AD genetics community as they provide a strong functional rationale to mechanistically follow-up novel AD-risk candidates. Author SummaryRisk genes give us insight into the failing molecular mechanisms that drive disease phenotypes. However, these risk genes are several layers of complexity removed from the emergent phenotypes they are influencing, the p-value that denotes their risk status gives little insight into the functional implications of that risk, and it is not clear when that risk gene may be having its effect. Methods like network-based functional prediction start to address several of these limitations by contextualizing risk genes in their broader genetic neighborhood within disease-relevant tissues. For complex diseases like Alzheimers, there are many possible relevant tissues incorporating everything from individual brain cell types to whole lobes of the brain. The work in this paper expands upon the traditional network-based functional prediction approach by considering a genes connections in multiple relevant tissue networks to prioritize candidate genes. Unlike traditional genetic risk studies, this kind prioritization benefits the Alzheimers genetics community as it provides a strong functional rationale to mechanistically follow-up on novel gene candidates.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Brabec, J. L., Lara, M. K., Tyler, A. L., Mahoney, J. M.. 2023-05-03. A multi-network approach to Alzheimers Disease gene prioritization complements cis-regulatory prioritization with molecular quantitative trait loci. https://doi.org/10.1101/2023.05.03.539189

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Mechanism-selective deep mutational scanning distinguishes ERCC2 disease phenotypes

Pathogenic ERCC2 variants cause xeroderma pigmentosum (XP), trichothiodystrophy (TTD) or both, yet variant effect scores are usually interpreted only as measures of pathogenicity rather than of which disease mechanism is disrupted. XPD, the ERCC2-encoded TFIIH subunit, functions in both nucleotide excision repair and transcription. Using yeast complementation deep mutational scanning, we measured the effects of nearly all XPD amino acid substitutions. The assay was mechanism-selective: it preferentially reported transcription-associated function, with pronounced intolerance at the p44 interface, whereas many substitutions affecting DNA binding and helicase activity retained near-wild-type fitness. Accordingly, TTD variants had much lower fitness than XP variants. Computational predictors discriminated pathogenic from benign variants similarly across phenotypes, but the DMS distinguished XP from TTD variants better than all 73 predictors tested. Phenotype-specific ACMG/AMP calibration provided evidence in both directions for TTD but mainly pathogenic evidence for XP. Thus, the selectivity of functional assays, often viewed as a limitation, can reveal disease mechanisms and support phenotype-aware variant interpretation.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗